Clinical Trial Detail

NCT ID NCT02758132
Title Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
Recruitment Terminated
Gender male
Phase Phase I
Variant Requirements No
Sponsors University of Hawaii
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Denosumab + Enzalutamide + Prednisone

Denosumab + Enzalutamide

Age Groups: adult

No variant requirements are available.